Dopamine receptor agonists in the treatment of advanced Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Stocchi, Fabrizio ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Continuous dopaminergic stimulation; Dopamine receptor agonist; Dyskinesia; Motor complications; Parkinson's disease

Indexed keywords

APOMORPHINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; ANTIPARKINSON AGENT;

ARTICLE; BASAL GANGLION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DYSKINESIA; ERYTHEMA; HALLUCINATION; HUMAN; INJECTION SITE REACTION; LEG SWELLING; LONG TERM CARE; MOTOR DYSFUNCTION; NAUSEA; NIGRONEOSTRIATAL SYSTEM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SKIN PRURITUS; SOMNOLENCE; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; VALVULAR HEART DISEASE; YAWNING; ANIMAL; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 72649083402     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70836-3     Document Type: Article

References (65)

1. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 11 Suppl 5 (2001) S1-S88
2. Agid Y., Olanow C.W., and Mizuno Y. Levodopa: why the controversy?. Lancet 360 (2002) 575
3. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., and Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 (2002) 11-17
4. Rascol O., Goetz C., Koller W., Poewe W., and Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359 (2002) 1589-1598
5. Korczyn A.D., and Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 62 (2002) 775-786
6. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
7. Marsden C.D. Parkinson's disease. J Neurol Neurosurg Psychiatry 57 (1994) 672-681
8. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 7 (1992) 117-124
9. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., and Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 9 (1994) 2-12
10. Melamed E., Bitton V., and Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 36 (1986) 100-103
11. Stacy M., Bowron A., Guttman M., Hauser R., Hughes K., Larsen J.P., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 (2005) 726-733
12. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5 (2006) 677-687
13. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
14. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 80 (1998) 1-27
15. Abercrombie E.D., Bonatz A.E., and Zigmond M.J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525 (1990) 36-44
16. Venton B.J., Zhang H., Garris P.A., Phillips P.E., Sulzer D., and Wightman R.M. Real-time decoding of dopamine concentrating changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87 (2004) 1284-1295
17. Calabresi P., Mercuri N.B., Sancesario G., and Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116 (1993) 433-452
18. Centonze D., Gubellini P., Picconi B., Calabresi P., Giacomini P., and Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol 82 (1999) 3575-3579
19. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
20. Rodríguez M., González J., Sabaté M., Obeso J., and Pereda E. Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons. Eur J Neurosci 18 (2003) 53-60
21. Stephens B., Mueller A.J., Shering A.F., Hood S.H., Taggart P., Arbuthnott G.W., et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 132 (2005) 741-754
22. Zaja-Milatovic S., Milatovic D., Schantz A.M., Zhang J., Montine K.S., Samii A., et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64 (2005) 545-547
23. Tremblay L., Filion M., and Bédard P.J. Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism. Brain Res 498 (1989) 17-33
24. Filion M., Tremblay L., and Bédard P.J. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 444 (1988) 165-176
25. Abercrombie E.D., Bonatz A.E., and Zigmond M.J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525 (1990) 36-44
26. De la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (2004) 2747-2754
27. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
28. 3H]spiperone binding. Brain Res 379 (1986) 294-299
29. Pearce R.K., Banerji T., Jenner P., and Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13 (1998) 234-241
30. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 47 4 Suppl 1 (2000) S90-S99
31. Blanchet P.J., Calon F., Martel J.C., Bédard P.J., Di Paolo T., Walters R.R., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272 (1995) 854-859
32. Bibbiani F., Costantini L.C., Patel R., and Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192 (2005) 73-78
33. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bédard P.J., et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49 (1997) 55-62
34. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
35. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di Paolo T., et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47 4 Suppl 1 (2000) S70-S78
36. Cenci M.A., Tranberg A., Andersson M., and Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94 (1999) 515-527
37. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bédard P.J., and Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61 (2002) 186-196
38. Boraud T., Bezard E., Bioulac B., and Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124 (2001) 546-557
39. Brown P., Oliviero A., Mazzone P., Insola A., Tonali P., and Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21 (2001) 1033-1038
40. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25 (1989) 473-478
41. Engber T.M., Susel Z., Juncos J.L., and Chase T.N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168 (1989) 291-298
42. Engber T.M., Susel Z., Kuo S., Gerfen C.R., and Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552 (1991) 113-118
43. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
44. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 284 (2000) 1931-1938
45. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54 (2003) 93-101
46. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
47. Nutt J.G., Obeso J.A., and Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S109-S115
48. Stocchi F., Ruggieri S., Vacca L., and Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 (2002) 2058-2066
49. Olanow C.W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 9 (1994) 40-47
50. Lieberman A., Olanow C.W., Sethi K., Swanson P., Waters C.H., Fahn S., et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51 (1998) 1057-1062
51. Pinter M.M., Pogarell O., and Oertel W.H. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 66 (1999) 436-441
52. Clarke C.E., and Deane K.H. Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 1 (2001) CD001518.
53. Talati R., Baker W.L., Patel A.A., Reinhart K., and Coleman C.I. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int J Clin Pract 63 (2009) 613-623
54. Stocchi F., Vacca L., Berardelli A., Onofrj M., Manfredi M., and Ruggieri S. Dual dopamine agonist treatment in Parkinson's disease. J Neurol 250 (2003) 822-826
55. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68 (2007) 1108-1115
56. LeWitt P.A., Lyons K.E., Pahwa R., and SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68 (2007) 1262-1267
57. Stocchi F. Pathological gambling in Parkinson's disease. Lancet Neurol 4 (2005) 590-592
58. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 (2003) 422-423
59. Nirenberg M.J., and Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21 (2006) 524-529
60. Brodsky M.A., Godbold J., Roth T., and Olanow C.W. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 18 (2003) 668-672
61. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
62. Frankel J.P., Lees A.J., Kempster P.A., and Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 53 (1990) 96-101
63. Hughes A.J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A.J., et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 8 (1993) 165-170
64. Dewey Jr. R.B., Hutton J.T., LeWitt P.A., and Factor S.A. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58 (2001) 1385-1392
65. Stocchi F. Use of apomorphine in Parkinson's disease. Neurol Sci 29 Suppl 5 (2008) S383-S386